Advertisement

Pharmaceutical Research

, Volume 24, Issue 8, pp 1508–1516 | Cite as

Ionically Fixed Polymeric Nanoparticles as a Novel Drug Carrier

  • Sa-Won Lee
  • Dong-Hoon Chang
  • Myung-Seop Shim
  • Bong-Oh Kim
  • Sun-Ok Kim
  • Min-Hyo SeoEmail author
Research Paper

Abstract

Purpose

In this study, we have prepared a novel polymeric drug delivery system comprised of ionically fixed polymeric nanoparticles (IFPN) and investigated their potential as a drug carrier for the passive targeting of water-insoluble anticancer drugs.

Materials and Methods

For this purpose, the physicochemical characteristics of the IFPN were investigated by comparing them with conventional polymeric micelles. IFPN containing paclitaxel were prepared and evaluated for in vitro stability and in vivo pharmacokinetics.

Results

The IFPN were successfully fabricated using a monomethoxypolyethylene glycol-polylactide (mPEG-PLA) diblock copolymer and a sodium salt of d,l-poly(lactic acid) (d,l-PLACOONa) upon the addition of CaCl2. The transmittance of the IFPN solution was much lower than that of a polymeric micelle solution at the same polymer concentration implicating an increase in the number of appreciable particles. The particle size of the IFPN was approximately 20∼30 nm which is in the range of particle sizes that facilitate sterile filtration using a membrane filter. The IFPN also have a regular spherical shape with a narrow size distribution. The zeta potential of the IFPN was almost neutral, similar to that of the polymeric micelles. In contrast, mixed micelles with a combination of mPEG-PLA and d,l-PLACOONa prior to the addition of Ca2+ showed a negative charge (−17 mV), possibly due to the carboxyl anion of polylactic acid exposed on the surface of the micelles. The IFPN formulation was highly kinetically stable in aqueous medium compared to the polymeric micelle formulation. The molecular weight of d,l-PLACOONa in the IFPN and the mPEG-PLA/d,l-PLACOONa molar ratio had a great influence upon the kinetic stability of the IFPN. Pharmacokinetic studies showed that the area under the concentration vs time curve (AUC) of IFPN in blood was statistically higher (about two times) when compared with that of Cremophor EL-based formulation (Taxol® equivalent) or polymeric micelle formulation.

Conclusions

The results suggests that the IFPN were retained in the circulation long enough to play a significant role as a drug carrier in the bloodstream, possibly resulting in improved therapeutic efficiency. Therefore, the IFPN are expected to be a promising novel polymeric nanoparticulate system for passive tumor targeting of water-insoluble anticancer drugs including paclitaxel.

Key words

d,l-PLACOONa ionically fixed polymeric nanoparticles long circulating carrier mPEG-PLA paclitaxel 

Notes

Acknowledgements

We would like to thank Dr. Chad Brown of Samyang Research Corporation for his valuable comments. This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A040020).

References

  1. 1.
    L. Mu and S. S. Feng. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J. Control. Release 80(1–3):129–144 (2002).PubMedCrossRefGoogle Scholar
  2. 2.
    S. Y. Kim and Y. M. Lee. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone) as novel anticancer drug carriers. Biomaterials 22(13):1697–1704 (2001).PubMedCrossRefGoogle Scholar
  3. 3.
    H. Suh, B. Jeong, R. Rathi, and S. W. Kim. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres. J. Biomed. Mater. Res. 42(2):331–338 (1998).PubMedCrossRefGoogle Scholar
  4. 4.
    S. Peltier, J. M. Oger, F. Lagarce, W. Couet, and J. P. Benoit. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm. Res. 23(6):1243–1250 (2006).PubMedCrossRefGoogle Scholar
  5. 5.
    J. A. Zhang, G. Anyarambhatla, L. Ma, S. Ugwu, T. Xuan, T. Sardone, and I. Ahmad. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur. J. Pharm. Biopharm. 59(1):177–187 (2005).PubMedCrossRefGoogle Scholar
  6. 6.
    M. L. Immordino, P. Brusa, S. Arpicco, B. Stella, F. Dosio, and L. Cattel. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control. Release 91(3):417–429 (2003).PubMedCrossRefGoogle Scholar
  7. 7.
    Z. Gao, A. N. Lukyanov, A. R. Chakilam, and V. P. Torchilin. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J. Drug Target. 11(2):87–92 (2003).PubMedCrossRefGoogle Scholar
  8. 8.
    A. Krishnadas, I. Rubinstein, and H. Onyuksel. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm. Res. 20(2):297–302 (2003).PubMedCrossRefGoogle Scholar
  9. 9.
    W. J. Gradishar. Albumin-bound nanoparticle paclitaxel. Clin. Adv. Hematol. Oncol. 3(5):348–349 (2005).PubMedGoogle Scholar
  10. 10.
    D. Papahadjopoulos and A. Gabizon. Liposomes designed to avoid the reticuloendothelial system. Prog. Clin. Biol. Res. 343:85–93 (1990).PubMedGoogle Scholar
  11. 11.
    R. H. Muller, S. Maassen, H. Weyhers, and W. Mehnert. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J. Drug Target. 4(3):161–170 (1996).PubMedGoogle Scholar
  12. 12.
    R. Gref, M. Luck, P. Quellec, M. Marchand, E. Dellacherie, S. Harnisch, T. Blunk, and R. H. Muller. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf., B Biointerfaces 18(3–4):301–313 (2000).CrossRefGoogle Scholar
  13. 13.
    I. Brigger, J. Morizet, G. Aubert, H. Chacun, M. J. Terrier-Lacombe, P. Couvreur, and G. Vassal. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Ther. 303(3):928–936 (2002).PubMedCrossRefGoogle Scholar
  14. 14.
    I. Brigger, P. Chaminade, V. Marsaud, M. Appel, M. Besnard, R. Gurny, M. Renoir, and P. Couvreur. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int. J. Pharm. 214(1–2):37–42 (2001).PubMedCrossRefGoogle Scholar
  15. 15.
    R. Gref, Y. Minamitake, M. T. Peracchia, A. Domb, V. Trubetskoy, V. Torchilin, and R. Langer. Poly(ethylene glycol)-coated nanospheres: potential carriers for intravenous drug administration. Pharm. Biotechnol. 10:167–198 (1997).PubMedCrossRefGoogle Scholar
  16. 16.
    R. T. Liggins and H. M. Burt. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv. Drug Deliv. Rev. 54:191–202 (2002).PubMedCrossRefGoogle Scholar
  17. 17.
    S. C. Kim, D. W. Kim, Y. H. Shim, J. S. Bang, H. S. Oh, S. W. Kim, and M. H. Seo. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J. Control. Release 72:191 (2001).PubMedCrossRefGoogle Scholar
  18. 18.
    H. M. Burt, X. Zhang, P. Toleikis, L. Embree, and W. L. Hunter. Development of copolymers of poly(D,L-lacitde) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Coll. Surf., B Biointerfaces 16:161 (1999).CrossRefGoogle Scholar
  19. 19.
    K. Avgoustakis, A. Beletsi, Z. Panagi, P. Klepetsanis, E. Livaniou, G. Evangelatos, and D. S. Ithakissios. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int. J. Pharm. 259:115–127 (2003).PubMedCrossRefGoogle Scholar
  20. 20.
    M. T. Peracchia, R. Gref, Y. Minamitake, A. Domb, N. Lotan, and R. Langer. PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: Investigation of their drug encapsulation and release characteristics. J. Control. Release 46:223–231 (1997).CrossRefGoogle Scholar
  21. 21.
    K. J. Zhu, L. Xiangzhou, and Y. Shilin. Preparation, characterization and properties of polylactide(PLA)-poly(ethylene glycol) (PEG) copolymers: a potential drug carrier. J. Appl. Polym. Sci. 39:1–9 (1990).CrossRefGoogle Scholar
  22. 22.
    B. Jeong, Y. H. Bae, D. S. Lee, and S. W. Kim. Biodegradable block copolymers as injectable drug delivery systems. Nature 388:860–862 (1997).PubMedCrossRefGoogle Scholar
  23. 23.
    A. J. ten Tije, J. Verweij, W. J. Loos, and A. Sparreboom. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 42(7):665–685 (2003).PubMedCrossRefGoogle Scholar
  24. 24.
    R. T. Dorr. Pharmacology and toxicology of Cremophor EL diluent. Ann. Pharmacother. 28:S11–S14 (1994).PubMedGoogle Scholar
  25. 25.
    H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37(13):1590–1598 (2001).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Sa-Won Lee
    • 1
  • Dong-Hoon Chang
    • 1
  • Myung-Seop Shim
    • 1
  • Bong-Oh Kim
    • 1
  • Sun-Ok Kim
    • 1
  • Min-Hyo Seo
    • 1
    Email author
  1. 1.Department of Parenteral Delivery ProgramSamyang Pharmaceuticals R&DDaejeonSouth Korea

Personalised recommendations